Via Nova Therapeutics is a technology company.
Via Nova Therapeutics has raised $20.0M across 1 funding round.
Via Nova Therapeutics has raised $20.0M in total across 1 funding round.
Via Nova Therapeutics is a biotechnology company focused on discovering and developing novel antiviral therapies targeting acute and subacute viral infections, including influenza A, human rhinovirus, BK polyomavirus, and adenovirus. Their mission centers on addressing significant unmet medical needs in virology by leveraging state-of-the-art drug discovery technologies to create first-in-class antivirals. The company serves patients affected by viral diseases for which current treatments are inadequate or lacking, aiming to bring these therapies efficiently to clinical use. Via Nova has demonstrated growth momentum by advancing its lead candidate, VNT-101, an influenza A nucleoprotein inhibitor, into clinical trials following FDA IND clearance[1][4][5].
Founded in 2020 and headquartered in Oakland, California, Via Nova Therapeutics emerged from the in-licensing of antiviral programs from Novartis. The company was co-founded by Don Ganem, MD, who also serves as CEO. The idea for Via Nova arose from recognizing the next frontier in antiviral therapy lies in acute and subacute infections, which have been underserved by existing treatments. Early pivotal moments include securing $20 million in funding and achieving FDA clearance to begin clinical evaluation of their novel influenza antiviral, marking a significant milestone in their development trajectory[4][5].
Via Nova is riding the trend of precision antiviral drug discovery, addressing the urgent global need for effective treatments against viral infections that cause significant morbidity and mortality. The timing is critical due to increasing viral resistance to existing drugs and the ongoing threat of viral outbreaks. Market forces favor companies that can rapidly develop novel antivirals with broad activity and improved safety profiles. Via Nova’s work influences the broader ecosystem by advancing innovative antiviral platforms and demonstrating efficient drug development models that integrate rapid diagnostics and telemedicine advancements[1][2][4].
Looking ahead, Via Nova Therapeutics is poised to advance its clinical pipeline further, potentially expanding its antiviral portfolio to cover additional viral pathogens. Trends shaping their journey include growing demand for novel antivirals amid rising viral resistance and the integration of digital health tools to enhance treatment delivery. Their influence may evolve as a key player in next-generation antiviral therapies, contributing to improved global health outcomes by addressing critical gaps in viral disease treatment. Their progress with VNT-101 and subsequent candidates will be important to watch as they seek to transform the treatment landscape for acute viral infections[1][4][6].
Via Nova Therapeutics has raised $20.0M in total across 1 funding round.
Via Nova Therapeutics's investors include Aditum Bio, Atlas Venture.
Via Nova Therapeutics has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $20.0M Series A | Aditum Bio, Atlas Venture |